Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML
Key Takeaways The combination therapy achieved a 91% overall response rate, with 45% complete remission and 46% marrow complete remission rates. Median overall survival was 30 months, with 1- and 3-year survival rates of 68.8% and 40.7%, respectively. SHOW MORE Decitabine…
